← Back to Search

E-Selectin Antagonist

Uproleselan for Coronavirus Pneumonia

Phase 1 & 2
Waitlist Available
Research Sponsored by Lena Napolitano, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during hospitalization; hospital stay ranged from 2 to 10 days
Awards & highlights

Study Summary

This trial will test if the drug uproleselan can help people with severe COVID-19 pneumonia recover more quickly and slow down the progression of acute respiratory failure.

Eligible Conditions
  • Coronavirus Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during hospitalization; hospital stay ranged from 2 to 10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and during hospitalization; hospital stay ranged from 2 to 10 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of Uproleselan - as Measured by Serious Adverse Events
Safety of Uproleselan- as Measured by Frequency of Serious Adverse Events
Secondary outcome measures
Actual Duration of Hospitalization
Actual Duration of ICU Care
All-cause Mortality
+9 more

Side effects data

From 2022 Phase 2 trial • 51 Patients • NCT04682405
100%
Diarrhea
100%
White blood cell decreased
100%
Neutrophil count decreased
100%
Platelet count decreased
100%
Hypocalcemia
96%
Anemia
96%
Nausea
92%
Lymphocyte count decreased
88%
Hypoalbuminemia
88%
Fatigue
81%
INR increased
81%
Abdominal Pain
81%
Hypophosphatemia
69%
Hypokalemia
65%
Vomiting
50%
Esophageal Pain
50%
Mucositis oral
38%
Esophagitis
35%
Enterocolitis
35%
Fever
35%
Malaise
35%
Constipation
31%
Hyponatremia
31%
Hypotension
27%
Thrush
23%
Gastritis
23%
Dizziness
19%
Back Pain
19%
Hemorrhoids
15%
Anorexia
15%
Edema Limbs
15%
Proctitis
12%
Gastroesophageal Reflux Disease
12%
Skin Infection
12%
Infections and Infestations - other
12%
Hyperglycemia
12%
Enterocolitis Infectious
12%
Alanine aminotransferase increased
12%
Blood bilirubin increased
12%
Dehydration
12%
Eye Disorders - other
12%
Activated partial thromboplastin time prolonged
12%
Musculoskeletal and Connective Tissue Disorder - other
8%
Creatinine increased
8%
Skin and Subcutaneous Tissue Disorders - other
8%
Aspartate aminotransferase increased
8%
Febrile neutropenia
8%
Headache
8%
Anxiety
8%
Dyspnea
8%
Wheezing
8%
Peripheral Sensory Neuropathy
8%
Generalized Muscle Weakness
8%
Hypernatremia
8%
Flatulence
8%
Periorbital Edema
8%
Hypoglycemia
8%
Pain in Extremity
8%
Bruising
8%
Hyperphosphatemia
8%
Bloating
8%
Infusion Site Extravasation
4%
Neoplasms benign, malignant, and unspecified (incl cysts and polyps) - other
4%
Muscle Cramp
4%
Psychiatric Disorders - other
4%
Testicular Pain
4%
Confusion
4%
Respiratory, Thoracic, and Mediastinal Disorders - other
4%
Sinus Tachycardia
4%
Dry Mouth
4%
Adrenal Insufficiency
4%
Generalized Edema
4%
Urinary Tract Infection
4%
Facial Pain
4%
Chills
4%
Vision Decreased
4%
Hyperkalemia
4%
Lethargy
4%
Insomnia
4%
Allergic Rhinitis
4%
Dysphagia
4%
Alkaline phosphatase increased
4%
Fall
4%
Blurred Vision
4%
Dysuria
4%
Nasal Congestion
4%
Localized Edema
4%
Bacteremia
4%
Sepsis
4%
Pulmonary Edema
4%
Restlessness
4%
Hematuria
4%
Cough
4%
Hypertension
4%
Lung Infection
4%
Papulopustular Rash
4%
Non-cardiac Chest Pain
4%
Delirium
4%
Encephalopathy
4%
Toothache
4%
Sinusitis
4%
Extraocular Muscle Paresis
4%
Hallucinations
4%
Otitis Externa
4%
Nervous System Disorders - other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Uproleselan + Standard of Care Melphalan
Placebo + Standard of Care Melphalan

Trial Design

1Treatment groups
Experimental Treatment
Group I: UproleselanExperimental Treatment1 Intervention
Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Uproleselan
2018
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Lena Napolitano, MDLead Sponsor
GlycoMimetics IncorporatedIndustry Sponsor
22 Previous Clinical Trials
1,506 Total Patients Enrolled
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top